WO2022239915A1 - 마이크로니들 패치, 마이크로니들 패치의 제조 방법 및 마이크로니들 패치의 제조 장치 - Google Patents
마이크로니들 패치, 마이크로니들 패치의 제조 방법 및 마이크로니들 패치의 제조 장치 Download PDFInfo
- Publication number
- WO2022239915A1 WO2022239915A1 PCT/KR2021/015027 KR2021015027W WO2022239915A1 WO 2022239915 A1 WO2022239915 A1 WO 2022239915A1 KR 2021015027 W KR2021015027 W KR 2021015027W WO 2022239915 A1 WO2022239915 A1 WO 2022239915A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- base material
- mold
- microneedle patch
- microneedle
- manufacturing
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 106
- 239000000463 material Substances 0.000 claims abstract description 261
- 238000001035 drying Methods 0.000 claims abstract description 42
- 238000000034 method Methods 0.000 claims abstract description 30
- 239000007853 buffer solution Substances 0.000 claims description 157
- 239000004480 active ingredient Substances 0.000 claims description 79
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 41
- 229920002674 hyaluronan Polymers 0.000 claims description 40
- 229960003160 hyaluronic acid Drugs 0.000 claims description 40
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000010410 layer Substances 0.000 description 89
- 238000002347 injection Methods 0.000 description 31
- 239000007924 injection Substances 0.000 description 31
- 210000003491 skin Anatomy 0.000 description 17
- 238000010586 diagram Methods 0.000 description 14
- 230000000052 comparative effect Effects 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- -1 dex Tran Sulfate Polymers 0.000 description 8
- 229920000642 polymer Polymers 0.000 description 7
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 6
- 239000001856 Ethyl cellulose Substances 0.000 description 5
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 5
- 239000000853 adhesive Substances 0.000 description 5
- 230000001070 adhesive effect Effects 0.000 description 5
- 238000009792 diffusion process Methods 0.000 description 5
- 238000012377 drug delivery Methods 0.000 description 5
- 235000019325 ethyl cellulose Nutrition 0.000 description 5
- 229920001249 ethyl cellulose Polymers 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000007704 transition Effects 0.000 description 5
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 4
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 4
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 4
- 239000000560 biocompatible material Substances 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 3
- 229920002101 Chitin Polymers 0.000 description 3
- 229920000858 Cyclodextrin Polymers 0.000 description 3
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 229940014041 hyaluronate Drugs 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 2
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 description 2
- 102400000739 Corticotropin Human genes 0.000 description 2
- 101800000414 Corticotropin Proteins 0.000 description 2
- 108010066486 EGF Family of Proteins Proteins 0.000 description 2
- 102000018386 EGF Family of Proteins Human genes 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 108700012941 GNRH1 Proteins 0.000 description 2
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 2
- 102000018997 Growth Hormone Human genes 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 108010039918 Polylysine Proteins 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 239000011149 active material Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 238000006065 biodegradation reaction Methods 0.000 description 2
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 229940045110 chitosan Drugs 0.000 description 2
- 229940059329 chondroitin sulfate Drugs 0.000 description 2
- 229940047120 colony stimulating factors Drugs 0.000 description 2
- 229960000258 corticotropin Drugs 0.000 description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 229960000633 dextran sulfate Drugs 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- PEASPLKKXBYDKL-FXEVSJAOSA-N enfuvirtide Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C1=CN=CN1 PEASPLKKXBYDKL-FXEVSJAOSA-N 0.000 description 2
- 239000005038 ethylene vinyl acetate Substances 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 2
- 229960000511 lactulose Drugs 0.000 description 2
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 229960000292 pectin Drugs 0.000 description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000656 polylysine Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000004003 subcutaneous fat Anatomy 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- BJFIDCADFRDPIO-DZCXQCEKSA-N (2S)-N-[(2S)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-13-(phenylmethyl)-1,2-dithia-5,8,11,14,17-pentazacycloeicos-4-yl]-oxomethyl]-2-pyrrolidinecarboxamide Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1 BJFIDCADFRDPIO-DZCXQCEKSA-N 0.000 description 1
- OVVIBUHLQIYUEU-IWIISZHXSA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-[[(2s,3s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[2-[[2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminometh Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 OVVIBUHLQIYUEU-IWIISZHXSA-N 0.000 description 1
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- PUDHBTGHUJUUFI-SCTWWAJVSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-p Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 PUDHBTGHUJUUFI-SCTWWAJVSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 102400000113 Calcitonin Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 1
- GJKXGJCSJWBJEZ-XRSSZCMZSA-N Deslorelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CNC2=CC=CC=C12 GJKXGJCSJWBJEZ-XRSSZCMZSA-N 0.000 description 1
- 102400000239 Dynorphin A(1-13) Human genes 0.000 description 1
- 108010032976 Enfuvirtide Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010056764 Eptifibatide Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102400000932 Gonadoliberin-1 Human genes 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 101500026183 Homo sapiens Gonadoliberin-1 Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 101150088952 IGF1 gene Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000004125 Interleukin-1alpha Human genes 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 108010048179 Lypressin Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 108010021717 Nafarelin Proteins 0.000 description 1
- AYRXSINWFIIFAE-UHFFFAOYSA-N O6-alpha-D-Galactopyranosyl-D-galactose Natural products OCC1OC(OCC(O)C(O)C(O)C(O)C=O)C(O)C(O)C1O AYRXSINWFIIFAE-UHFFFAOYSA-N 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- 102400000050 Oxytocin Human genes 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 102100037505 Secretin Human genes 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 108010010056 Terlipressin Proteins 0.000 description 1
- 108010078233 Thymalfasin Proteins 0.000 description 1
- 102400000160 Thymopentin Human genes 0.000 description 1
- 101800001703 Thymopentin Proteins 0.000 description 1
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 1
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 1
- DRQXUCVJDCRJDB-UHFFFAOYSA-N Turanose Natural products OC1C(CO)OC(O)(CO)C1OC1C(O)C(O)C(O)C(CO)O1 DRQXUCVJDCRJDB-UHFFFAOYSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 125000005211 alkyl trimethyl ammonium group Chemical group 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229960001500 bivalirudin Drugs 0.000 description 1
- 108010055460 bivalirudin Proteins 0.000 description 1
- OIRCOABEOLEUMC-GEJPAHFPSA-N bivalirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 108700021293 carbetocin Proteins 0.000 description 1
- 229960001118 carbetocin Drugs 0.000 description 1
- NSTRIRCPWQHTIA-DTRKZRJBSA-N carbetocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSCCCC(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(OC)C=C1 NSTRIRCPWQHTIA-DTRKZRJBSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229960002798 cetrimide Drugs 0.000 description 1
- 108700008462 cetrorelix Proteins 0.000 description 1
- 229960003230 cetrorelix Drugs 0.000 description 1
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 description 1
- DDPFHDCZUJFNAT-PZPWKVFESA-N chembl2104402 Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CCCCCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 DDPFHDCZUJFNAT-PZPWKVFESA-N 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960005408 deslorelin Drugs 0.000 description 1
- 108700025485 deslorelin Proteins 0.000 description 1
- 229960004281 desmopressin Drugs 0.000 description 1
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 108010074881 dynorphin (1-13) Proteins 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 108700032313 elcatonin Proteins 0.000 description 1
- 229960000756 elcatonin Drugs 0.000 description 1
- 229960002062 enfuvirtide Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- GLGOPUHVAZCPRB-LROMGURASA-N eptifibatide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCCNC(=N)N)NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]1CC1=CN=C2[C]1C=CC=C2 GLGOPUHVAZCPRB-LROMGURASA-N 0.000 description 1
- 229960004468 eptifibatide Drugs 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- DLRVVLDZNNYCBX-CQUJWQHSSA-N gentiobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-CQUJWQHSSA-N 0.000 description 1
- 229960001442 gonadorelin Drugs 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 229920006158 high molecular weight polymer Polymers 0.000 description 1
- 108700020746 histrelin Proteins 0.000 description 1
- HHXHVIJIIXKSOE-QILQGKCVSA-N histrelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC(N=C1)=CN1CC1=CC=CC=C1 HHXHVIJIIXKSOE-QILQGKCVSA-N 0.000 description 1
- 229960002193 histrelin Drugs 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 229940076264 interleukin-3 Drugs 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 1
- 108010021336 lanreotide Proteins 0.000 description 1
- 229960002437 lanreotide Drugs 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960003837 lypressin Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- RWHUEXWOYVBUCI-ITQXDASVSA-N nafarelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 description 1
- 229960002333 nafarelin Drugs 0.000 description 1
- 229960002700 octreotide Drugs 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940072644 pitressin Drugs 0.000 description 1
- 229920002006 poly(N-vinylimidazole) polymer Polymers 0.000 description 1
- 229920000111 poly(butyric acid) Polymers 0.000 description 1
- 239000002745 poly(ortho ester) Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920006149 polyester-amide block copolymer Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920002620 polyvinyl fluoride Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 229960003611 pramlintide Drugs 0.000 description 1
- 108010029667 pramlintide Proteins 0.000 description 1
- NRKVKVQDUCJPIZ-MKAGXXMWSA-N pramlintide acetate Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960002101 secretin Drugs 0.000 description 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 229960002959 sincalide Drugs 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 231100000245 skin permeability Toxicity 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- XTHPWXDJESJLNJ-UHFFFAOYSA-N sulfurochloridic acid Chemical compound OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229960003813 terlipressin Drugs 0.000 description 1
- BENFXAYNYRLAIU-QSVFAHTRSA-N terlipressin Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CN)CSSC1 BENFXAYNYRLAIU-QSVFAHTRSA-N 0.000 description 1
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 description 1
- 229960004231 thymalfasin Drugs 0.000 description 1
- 229960004517 thymopentin Drugs 0.000 description 1
- PSWFFKRAVBDQEG-YGQNSOCVSA-N thymopentin Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 PSWFFKRAVBDQEG-YGQNSOCVSA-N 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 108091008023 transcriptional regulators Proteins 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229960004824 triptorelin Drugs 0.000 description 1
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 1
- RULSWEULPANCDV-PIXUTMIVSA-N turanose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](C(=O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RULSWEULPANCDV-PIXUTMIVSA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- BPKIMPVREBSLAJ-QTBYCLKRSA-N ziconotide Chemical compound C([C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]2C(=O)N[C@@H]3C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC2)C(N)=O)=O)CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CSSC3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(N1)=O)CCSC)[C@@H](C)O)C1=CC=C(O)C=C1 BPKIMPVREBSLAJ-QTBYCLKRSA-N 0.000 description 1
- 229960002811 ziconotide Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C41/00—Shaping by coating a mould, core or other substrate, i.e. by depositing material and stripping-off the shaped article; Apparatus therefor
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C41/00—Shaping by coating a mould, core or other substrate, i.e. by depositing material and stripping-off the shaped article; Apparatus therefor
- B29C41/02—Shaping by coating a mould, core or other substrate, i.e. by depositing material and stripping-off the shaped article; Apparatus therefor for making articles of definite length, i.e. discrete articles
- B29C41/12—Spreading-out the material on a substrate, e.g. on the surface of a liquid
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C41/00—Shaping by coating a mould, core or other substrate, i.e. by depositing material and stripping-off the shaped article; Apparatus therefor
- B29C41/02—Shaping by coating a mould, core or other substrate, i.e. by depositing material and stripping-off the shaped article; Apparatus therefor for making articles of definite length, i.e. discrete articles
- B29C41/22—Making multilayered or multicoloured articles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0023—Drug applicators using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0046—Solid microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0053—Methods for producing microneedles
Definitions
- the present invention relates to a microneedle patch, a method for manufacturing a microneedle patch, and an apparatus for manufacturing a microneedle patch.
- Drug injection into the human body has traditionally been performed by needle injection, but needle injection causes great pain. Therefore, a non-invasive drug injection method has also been developed, but there is a problem in that the amount of drug required is too large compared to the amount of injection.
- DDS drug delivery system
- microneedles can be characterized by painless skin penetration and no trauma.
- a certain degree of physical hardness may be required because the microneedle must penetrate the stratum corneum of the skin.
- an appropriate length may be required in order for the physiologically active material to reach the epidermal layer or the dermal layer of the skin.
- the skin permeability of the "micro" needles must be high and maintained for a certain period of time until they are dissolved after being inserted into the skin.
- microneedles capable of delivering a drug in a precise amount and accurately setting a target position is increasing.
- the present invention can provide a microneedle patch, a method for manufacturing a microneedle patch, and a manufacturing apparatus capable of manufacturing a microneedle patch capable of effectively delivering an active ingredient to a target location in a quantitative amount.
- One aspect of the present invention includes filling a base material in a mold having a plurality of needle grooves, forming a pressure lower than atmospheric pressure in the mold, rotating the mold about a rotational axis, and A method for manufacturing a microneedle patch comprising drying the filled base material is provided.
- One aspect of the present invention includes filling a buffer solution in a mold having a plurality of needle grooves, disposing a base material on the needle grooves, diffusing the base material into the buffer solution, and the mold. It provides a method for manufacturing a microneedle patch comprising the step of drying.
- the apparatus for manufacturing a microneedle patch and the method for manufacturing a microneedle patch according to the present invention can manufacture a high-quality microneedle patch.
- the present invention forms a pressure lower than atmospheric pressure in the mold to remove the gas remaining inside the microneedle patch so that the microneedle does not contain foreign substances and removes the gas between the mold and the base material so that it is easy to attach to the target and drug delivery This effective microneedle patch can be prepared.
- the apparatus for manufacturing a microneedle patch and the method for manufacturing a microneedle patch according to the present invention can manufacture a high-quality microneedle patch.
- a vacuum is formed in the mold to remove the gas remaining inside the microneedle patch so that the microneedle does not contain foreign substances, and the gas between the mold and the base material is removed to obtain a microneedle patch that is easy to attach to the target and has effective drug delivery. can be manufactured
- FIG. 1 is a diagram showing an apparatus for manufacturing a microneedle patch according to an embodiment of the present invention.
- FIG. 2 is a perspective view illustrating the microneedle patch prepared in FIG. 1 .
- FIG. 3 is a diagram illustrating injection of a base material in the injection module of FIG. 1 .
- Figure 4 is a diagram showing the operation of the pressure module of Figure 1;
- FIG. 5 is an enlarged view of portion A of FIG. 4 .
- FIG. 6 is a diagram illustrating driving of the rotation module.
- FIG. 7 is a view showing filling a mold with a base material in part B of FIG. 6 .
- FIG. 8 is a flowchart illustrating a method of manufacturing a microneedle patch according to another embodiment of the present invention.
- FIG. 9 is a flowchart illustrating a method of manufacturing a microneedle patch according to another embodiment of the present invention.
- FIGS. 10 to 12 are views showing microneedle patches manufactured by the method of manufacturing a microneedle patch according to the present invention.
- FIG. 13 and 14 are diagrams showing a microneedle patch manufactured by the method of manufacturing a microneedle patch according to the present invention and a comparative example.
- 15 is a diagram showing an apparatus for manufacturing a microneedle patch according to another embodiment of the present invention.
- 16 is a flowchart illustrating a method of manufacturing a microneedle patch according to another embodiment of the present invention.
- 17 to 21 are diagrams illustrating manufacturing steps of microneedles by the method of manufacturing the microneedle patch of FIG. 16 .
- FIG. 22 is a view showing a microneedle patch manufactured by the method of manufacturing the microneedle patch of FIG. 16 .
- 23 to 25 are diagrams illustrating other embodiments of the microneedle patch of FIG. 22 .
- One aspect of the present invention includes filling a base material in a mold having a plurality of needle grooves, forming a pressure lower than atmospheric pressure in the mold, rotating the mold about a rotational axis, and A method for manufacturing a microneedle patch comprising drying the filled base material is provided.
- the base material may be brought into close contact with the needle groove in the axial direction by centrifugal force.
- the method may further include pre-rotating the mold filled with the base material with respect to the rotation shaft before the step of forming a pressure lower than atmospheric pressure in the mold.
- rotation axis may be perpendicular to the axial direction of the needle groove.
- Another aspect of the present invention is a mold having a plurality of needle grooves into which a base material is injected, a pressure module for forming a pressure lower than atmospheric pressure in the mold, a rotation module for rotating the mold around a rotation axis, and the needle
- An apparatus for manufacturing a microneedle patch including a drying module for drying the base material filled in the groove is provided.
- the base material is generated by the centrifugal force generated by driving the rotation module after internal bubbles of the base material are removed from the pressure module or gas between the base material and the needle groove is removed. It can be closely adhered to in the axial direction of the needle groove.
- One aspect of the present invention includes filling a buffer solution in a mold having a plurality of needle grooves, disposing a base material on the needle grooves, diffusing the base material into the buffer solution, and the mold. It provides a method for manufacturing a microneedle patch comprising the step of drying.
- the base material may be injected into the needle groove.
- the buffer solution may dissolve the base material.
- the buffer solution may include water
- the base material may include hyaluronic acid
- an active ingredient may be disposed inside the base material.
- the buffer solution may be removed and the base material may be hardened in the needle groove.
- microneedle patch comprising a base and a plurality of microneedles mounted on the base, wherein the microneedle dissolves a base material in a buffer solution and then dries the buffer solution.
- the buffer solution may include water
- the base material may include hyaluronic acid
- an active ingredient may be disposed inside the base material.
- FIG. 1 is a diagram showing an apparatus for manufacturing a microneedle patch according to an embodiment of the present invention.
- an apparatus 1 for manufacturing a microneedle patch may include an injection module 10 , a pressure module 20 , a rotation module 30 , and a drying module 40 .
- the microneedle patch manufacturing apparatus 1 shows that the injection module 10, the pressure module 20, the rotation module 30, and the drying module 40 are sequentially disposed one by one, but it is not limited thereto. and may be variously modified according to the manufacturing process of the microneedle patch.
- the microneedle patch manufacturing apparatus 1 may include a plurality of at least one of the injection module 10 , the pressure module 20 , the rotation module 30 , and the drying module 40 .
- the rotation module 30 may be disposed prior to the pressure module 20 .
- microneedle patch 100 manufactured by the microneedle patch manufacturing apparatus 1 a plurality of microneedles 120 may be disposed on the base 110.
- the microneedle patch 100 may be attached to an object to deliver drugs or cosmetic substances.
- FIG. 2 is a perspective view illustrating the microneedle patch prepared in FIG. 1 .
- the microneedle patch 100 may include a base 110 and microneedles 120 .
- the base 110 supports the microneedles 120 and may have a plurality of microneedles 120 on one surface. One side of the base 110 may be in contact with the skin, and the other side of the base 110 may be exposed to the outside.
- the base 110 may be removed when the microneedle 120 is implanted into the skin.
- the base may be removed from the skin by applying force by the user.
- a portion where the base 110 and the microneedle 120 are connected is first dissolved, and the base 110 may be removed after a predetermined time has elapsed after attachment.
- the base 110 may be dissolved.
- the base 110 may be removed by a user applying a material for dissolution.
- the base 110 may include any one of the materials included in the microneedle 120 .
- the base 110 may include a biodegradable material like the microneedle 120 .
- the base 110 may include a physiologically active material. After attaching the microneedle patch 100 to the skin, an effective drug can be effectively delivered to the patient by the physiologically active substance coming out of the base 110. In addition, the base 110 and the microneedle 120 can be easily separated by the physiologically active substance coming out of the base 110 .
- the base 110 may have a lower solubility than the layer most adjacent to the microneedle 120, that is, the layer most spaced apart from the tip of the microneedle 120. Since a portion of the microneedle 120 adjacent to the base 110 dissolves the fastest, the base 110 can be easily separated from the microneedle 120 .
- the base 110 may include a water-soluble polymer.
- the base 110 may be composed of a water-soluble polymer or may contain other additives (eg, disaccharides).
- the base 110 preferably does not contain drugs or active ingredients.
- Base 110 may include a biocompatible material.
- the base 110 may select a biocompatible material selected as a base material of the microneedle 120 to be described later as a base material.
- the microneedles 120 protrude from the surface of the base 110 and may be provided in plurality.
- the microneedle 120 is formed of a base material (BM), and the base material (BM) may include a biocompatible material and an additive.
- Biocompatible materials include carboxymethyl cellulose (CMC), hyaluronic acid (HA), alginic acid, pectin, carrageenan, chondroitin sulfate, dex Tran Sulfate, Chitosan, Polylysine, Carboxymethyl Chitin, Fibrin, Agarose, Pullulan, Polyanhydride , polyorthoester, polyetherester, polyesteramide, poly butyric acid, poly valeric acid, polyacrylate, Ethylene-vinyl acetate polymer, acrylic substituted cellulose acetate, polyvinyl chloride, polyvinyl fluoride, polyvinyl imidazole, chlorosulphonate polyolefins , polyethylene oxide, polyvinylpyrrolidone (PVP), hydroxypropylmethylcellulose (HPMC), ethylcellulose (EC), hydroxypropylcellulose (HPC), carboxymethylcellulose, cyclodextrin (Cyclodextrin),
- the additives are trehalose, oligosaccharide, sucrose, maltose, lactose, cellobiose, hyaluronic acid, alginic Alginic acid, Pectin, Carrageenan, Chondroitin Sulfate, Dextran Sulfate, Chitosan, Polylysine, Collagen, Gelatin, Carboxymethyl Chitin ( carboxymethyl chitin), fibrin, agarose, polyvinylpyrrolidone (PVP), polyethylene glycol (PEG), polymethacrylate, hydroxypropylmethylcellulose (HPMC), ethylcellulose (EC), Hydroxypropylcellulose (HPC), carboxymethyl cellulose, cyclodextrin, gentiobiose, alkyltrimethylammonium bromide (Cetrimide), hexadecyltrimethylammoniumbromide (CTAB) , Gentian Violet, benzethonium chloride, docus
- Hyaluronic acid is used to include not only hyaluronic acid but also hyaluronic acid salts (eg, sodium hyaluronate, potassium hyaluronate, magnesium hyaluronate and calcium hyaluronate) and mixtures thereof.
- Hyaluronic acid is used as a meaning including cross-linked hyaluronic acid and/or non-cross-linked hyaluronic acid.
- the hyaluronic acid of the present invention has a molecular weight of 2 kDa to 5000 kDa.
- the hyaluronic acid of the present invention has a molecular weight of 100-4500, 150-3500, 200-2500 kDa, 220-1500 kDa, 240-1000 kDa or 240-490 kDa.
- Carboxymethyl cellulose may use CMC of various known molecular weights.
- the average molecular weight of CMC used in the present invention is 90,000 kDa, 250,000 kDa or 700,000 kDa.
- the disaccharide may include sucrose, lactulose, lactose, maltose, trehalose, or cellobiose, and may include sucrose, maltose, or trehalose in particular.
- an adhesive may be included.
- the adhesive is at least one adhesive selected from the group consisting of silicone, polyurethane, hyaluronic acid, physical adhesive (Gecko), poly acrylic, ethyl cellulose, hydroxy methyl cellulose, ethylene vinyl acetate and polyisobutylene.
- the microneedle 120 may additionally include metal, a high molecular weight polymer, or an adhesive.
- the microneedle 120 may contain an active ingredient (EM). At least a portion of the microneedle 120 may include a pharmaceutical, medical or cosmetic active ingredient (EM).
- active ingredients include, but are not limited to, protein/peptide drugs, hormones, hormone analogues, enzymes, enzyme inhibitors, signaling proteins or parts thereof, antibodies or parts thereof, single chain antibodies, binding It includes at least one of proteins or binding domains thereof, antigens, adhesion proteins, structural proteins, regulatory proteins, toxin proteins, cytokines, transcriptional regulators, blood coagulation factors, and vaccines.
- the protein / peptide drug is insulin, IGF- 1 (insulinlike growth factor 1), growth hormone, erythropoietin, G-CSFs (granulocyte-colony stimulating factors), GM-CSFs (granulocyte / macrophage- colony stimulating factors), interferon alpha, interferon beta, interferon gamma, interleukin-1 alpha and beta, interleukin-3, interleukin-4, interleukin-6, interleukin-2, epidermal growth factors (EGFs), calcitonin , adrenocorticotropic hormone (ACTH), tumor necrosis factor (TNF), atobisban, buserelin, cetrorelix, deslorelin, desmopressin , dynorphin A (1-13), elcatonin, eleidosin, eptifibatide, growth hormone releasing hormone-II (GHRHII), gonadorelin ), goserelin, his
- the active ingredient (EM) may be a colloid dispersed in a solvent forming the microneedles 120 in the form of particulates.
- the fine particles themselves may be an active ingredient (EM) or may include a coating material carrying the active ingredient (EM).
- the active ingredient (EM) may be intensively distributed on a partial layer of the microneedle 120 . That is, since the active ingredient (EM) is disposed at a specific height in the microneedle 120, the active ingredient (EM) can be effectively delivered.
- the active ingredient (EM) may be dissolved in the microneedle 120 .
- the active ingredient (EM) may be dissolved in a base material of the microneedle 120 such as the aforementioned biodegradable materials to form the microneedle 120 .
- the active ingredient (EM) may be dissolved in the base material at a uniform concentration, and may be intensively distributed at a specific height of the microneedle 120 like the above-described fine particles.
- the microneedle patch 100 may have a plurality of active ingredients (EM) according to regions.
- EM active ingredients
- a microneedle of a first group contains a first active ingredient among the plurality of active ingredients
- a microneedle of a second group different from the first group contains a second active ingredient among the plurality of active ingredients.
- a pharmaceutical, medical or cosmetic active ingredient may be coated on the microneedle 120 .
- the active ingredients (EM) may be coated on the entire microneedle 120 or only a portion of the microneedle 120 .
- a portion of the coating layer of the microneedle 120 may be coated with the first active ingredient, and the other portion may be coated with the second active ingredient.
- the microneedle 120 may have various shapes.
- the microneedle 120 may have a cone shape.
- the microneedle 120 may have a polygonal shape such as a cone shape, a triangular pyramid shape, or a quadrangular pyramid shape.
- the microneedle 120 may have a layered structure.
- the microneedle 120 may have a plurality of stacked layers.
- the number of layers forming the microneedle 120 is not limited to a specific number.
- FIG. 3 is a diagram illustrating injection of a base material in the injection module of FIG. 1 .
- the base material BM may be injected into the mold M in the injection module 10 .
- the mold (M) has a base groove (BG) and a plurality of needle grooves (NG).
- the base groove BG is an area where the base 110 is manufactured
- the needle groove NG is an area where the microneedle 120 is manufactured, and the base material BM is injected into the needle groove NG.
- the base material BM is disposed on top of the needle groove NG and is injected into the needle groove NG.
- the base material BM may be injected into the mold M in various ways.
- the base material BM is a liquid, and may be sprayed from the nozzle 11 and injected into the mold M.
- the base material BM may be injected into the needle groove NG by dropping a droplet of the base material BM into the needle groove NG.
- the base material BM is in the form of a gel and may be disposed on the mold M using a spatula. Thereafter, the base material BM may be injected into the needle groove NG while being compressed by a squeezing device (not shown).
- Bubbles may be formed inside the base material BM injected into the mold M. Bubbles may be formed in the process of manufacturing the base material (BM), and bubbles may be formed in the process of injecting the base material (BM) into the mold (M). In addition, gas may be stored between the base material BM and the needle groove NG. In the process of injecting the base material BM, the gas may not be completely removed and may remain in the space between the needle groove NG and the base material BM.
- FIG. 4 is a view illustrating the operation of the pressure module of FIG. 1
- FIG. 5 is an enlarged view of portion A of FIG. 4 .
- the pressure module 20 is operated to remove gas remaining in the needle groove NG or to remove internal bubbles of the base material BM.
- forming the mold M at a low pressure by driving the pressure module 20 is a relatively low pressure to remove the gas inside the needle groove NG or to remove the bubbles inside the base material BM.
- forming the mold M at a low pressure by driving the pressure module 20 may mean forming the inside of the pressure chamber at a pressure lower than atmospheric pressure.
- forming the mold M at a low pressure by driving the pressure module 20 may mean setting the inside of the pressure chamber to 1 atm or less.
- forming the mold M at a low pressure by driving the pressure module 20 includes setting the inside of the pressure chamber to 1 mbar or less to create a substantially vacuum-like environment.
- the mold M is placed on the support 21 of the pressure module 20, and the pressure pump 22 is driven to form the inside of the pressure chamber at a low pressure.
- the low pressure may be set to a pressure lower than atmospheric pressure. Since a relatively low pressure is also formed in the needle groove NG of the mold M, the gas g in the internal bubble BU of the base material BM is removed. In addition, the gas (g) in the space between the base material (BM) and the needle groove (NG) is also removed.
- the pressure module 20 removes the gas (g) inside the base material (BM) or removes the gas (g) between the base material (BM) and the needle groove (NG), so that the microneedle ( 120) can be improved.
- the driving of the pressure pump 22 is stopped to release the pressure state of the mold (M) lower than atmospheric pressure.
- the internal bubble BU of the base material BM is maintained as an empty space, and the space between the surface of the needle groove NG and the base material BM is also maintained as an empty space.
- the mold M may maintain a pressure lower than atmospheric pressure. Thereafter, the base material BM may be filled in the empty space by driving the rotation module 30 while maintaining a low pressure state.
- FIG. 6 is a view showing the driving of the rotation module
- FIG. 7 is a view showing filling the mold with a base material in part B of FIG. 6 .
- the rotation module 30 rotates the mold M around the rotation axis RX to provide centrifugal force to the mold M.
- the axis of rotation (RX) is different from the longitudinal direction of the needle groove (NG).
- the longitudinal direction of the rotation axis (RX) and the needle groove (NG) is set to be different from each other.
- the longitudinal directions of the rotating shaft RX and the needle groove NG may be set perpendicular to each other.
- Centrifugal force (Fc) is formed along the longitudinal direction of the needle groove (NG), so that the base material (BM) completely fills the needle groove (NG).
- the base material BM By the centrifugal force, the base material BM is pushed to the end of the needle groove NG. At this time, the base material BM is also filled in the area of the needle groove NG where the base material BM was not previously filled. In addition, the base material BM is brought into close contact with the inside of the base material BM by the centrifugal force Fc, and the internal bubbles BU are removed.
- the gas g is removed from the area not filled with the base material BM and the internal bubble BU, so that the pressure is lower than that of the outside.
- the base material BM can quickly and simply fill the needle groove NG and the internal bubble BU.
- the rotation module 30 provides a centrifugal force (Fc) to the mold (M), so that the base material (BM) can be completely filled in the needle groove (NG).
- Fc centrifugal force
- the mold M can manufacture the sophisticated microneedles 120, and pores inside the microneedles 120 can be removed.
- the rotation module 30 may be driven prior to the pressure module 20 . That is, in the injection module 10, the base material BM is injected into the mold M, and the rotation module 30 is driven. By the centrifugal force (Fc) generated by the rotation module 30, the base material (BM) can be filled up to the tip of the needle groove (NG).
- Fc centrifugal force
- the pressure chamber described above is driven to remove the gas in the internal bubble of the base material BM or the gas between the base material BM and the needle groove NG. Then, the rotation module 30 is driven again, so that the needle groove NG can be completely filled with the base material BM.
- the drying module 40 dries the base material BM.
- the dried base material BM is completed with microneedles 120 .
- the microneedle patch 100 is separated from the mold M.
- FIG. 8 is a flowchart illustrating a method of manufacturing a microneedle patch according to another embodiment of the present invention.
- the method of manufacturing a microneedle patch includes filling a mold having a plurality of needle grooves with a base material (S10), forming a pressure lower than atmospheric pressure in the mold (S20), and turning the mold into a rotating shaft. rotating with respect to (S30), and drying the base material filled in the needle groove (S40).
- step S10 of filling a mold having a plurality of needle grooves with a base material the base material BM is injected into the mold M.
- the chamber in which the mold M is installed may be set to a low pressure. That is, even in the step of filling the mold having a plurality of needle grooves with the base material (S10), the internal pressure of the chamber may be maintained at a pressure lower than atmospheric pressure. As a result, it is possible to minimize the generation of bubbles inside the base material BM.
- a gas such as air may be stored therein in the form of a bubble BU. Even when the base material BM is injected into the needle groove NG, internal bubbles BU may still exist in the needle groove NG.
- the gas g remaining in the internal bubble BU of the base material BM may seriously degrade the quality of the microneedle 120 . Since the microneedle 120 is a part to be implanted into the skin of a subject, it should not contain foreign substances including gas. If the gas g in the bubble BU is injected into the object, it may threaten the safety of the object.
- the needle groove NG has a very small volume and the base material BM has a predetermined viscosity, it is difficult for the base material BM to completely fill the needle groove NG. Even when the base material BM is disposed in the needle groove NG, gas g may remain between the base material BM and the surface of the needle groove NG.
- the internal bubbles BU of the base material BM filled in the needle groove NG are removed or between the base material BM and the needle groove NG.
- of gas (g) can be removed.
- a pressure lower than atmospheric pressure is formed in the mold M, that is, the internal pressure of the chamber in which the mold M is mounted is set to a pressure lower than 1 atmosphere, so that the internal bubbles of the base material BM ( Gas (g) in the BU may be removed, and gas (g) remaining in the needle groove (NG) may be removed.
- the gas in the internal bubble (BU) is discharged to the outside of the mold (M).
- the gas stored between the surface of the base material (BM) and the needle groove (NG) is also discharged to the outside of the mold (M).
- step S30 In the step of rotating the mold with respect to the rotational axis (S30), centrifugal force is formed in the mold (M), so that the base material (BM) can be completely filled in the needle groove (NG).
- step S30 the base material BM is brought into close contact with the needle groove NG in the axial direction by centrifugal force.
- the low pressure state of the mold (M) is released before applying the centrifugal force to the mold (M). Thereafter, when the mold M is rotated about the rotational axis RX, the base material BM is deeply injected into the needle groove NG by centrifugal force.
- the mold M may be rotated about the rotational axis RX while maintaining the mold M at a pressure lower than atmospheric pressure. Since the mold M continuously maintains a low-pressure atmosphere, the base material BM is deeply injected into the needle groove NG by centrifugal force.
- the microneedle 120 is created by drying the base material BM filled in the mold M. Thereafter, the manufactured microneedle 120 may be removed from the mold M.
- FIG. 9 is a flowchart illustrating a method of manufacturing a microneedle patch according to another embodiment of the present invention.
- a step of rotating the mold filled with the base material (S15) may be further included.
- the mold (M) After injecting the base material (BM) into the mold (M), the mold (M) is rotated with respect to the rotation axis. Then, the base material BM is pushed deep into the needle groove NG by the generated centrifugal force.
- the base material BM When centrifugal force is primarily applied to the mold M filled with the base material BM, the base material BM may be uniformly distributed in the needle groove NG by the centrifugal force.
- the inside of the chamber in which the mold M is installed is set to a low pressure, the gas g is removed from the needle groove NG or the base material BM.
- centrifugal force is secondarily applied to the mold M again, the base material BM is completely brought into close contact with the needle groove NG by the centrifugal force, so that the quality of the microneedle 120 can be improved.
- a method of manufacturing a microneedle patch according to another embodiment of the present invention includes filling a mold having a plurality of needle grooves with a base material (S10), forming a pressure lower than atmospheric pressure in the mold (S20), All of the steps of rotating the mold about the axis of rotation (S30) may be performed in the same chamber.
- FIGS. 10 to 12 are views showing microneedle patches manufactured by the method of manufacturing a microneedle patch according to the present invention.
- the microneedle patch 100 may include a base 110 and single-layer microneedles 120 using the above-described microneedle patch manufacturing apparatus 1 or the microneedle patch manufacturing method.
- the microneedle 120 may contain an active ingredient (EM) therein.
- the microneedle patch 200 may be manufactured by the above-described microneedle patch manufacturing apparatus 1 or the microneedle patch manufacturing method.
- the microneedle patch 200 may have a base 210 and microneedles 220 having a multilayer structure.
- the microneedle patch 200 having a multilayer structure can be manufactured.
- the first layer is first layered by injecting the first base material into the needle groove NG, first forming a pressure lower than atmospheric pressure in the mold M, rotating the mold M, and drying the first base material. (221).
- the pressure primarily formed in the mold (M) and the pressure formed secondarily may be set to be different from each other.
- the secondly formed pressure has a lower pressure than the firstly formed pressure, so that the gas (g) remaining in the base material (BM) or the needle groove (NG) can be completely removed.
- the microneedles 220 disposed on one surface of the base 210 have a multi-layered structure, so that the active ingredient (EM) can be accurately delivered to the target point. Since the microneedle 220 has a multi-layered structure, active ingredients can be loaded into each layer. For example, the first active ingredient EM1 may be loaded on the first layer 221 and the second active ingredient EM2 may be loaded on the second layer 222 . Thus, the microneedle patch 100 can adjust the active depth of each active ingredient according to the height of the layer. That is, the microneedle patch 200 can deliver active ingredients to any one of epidermis, dermis, subcutaneous fat, and muscle.
- the microneedle patch 200 has a multi-layer structure, and the biodegradation rate of each layer can be set differently.
- the microneedle 220 sets the decomposition rate of the first layer 221 and the second layer 222 differently, so that the first active ingredient EM1 and the second active ingredient EM2 can have different active times. have.
- the microneedle patch 200 has a multi-layer structure, and the strength of each layer can be set differently. By setting the strength of the first layer 221 higher than that of the second layer 222, the microneedle 220 can be easily injected into the skin.
- the microneedle patch 200' may be manufactured by the above-described microneedle patch manufacturing apparatus 1 or the microneedle patch manufacturing method.
- the microneedle patch 200' may have a base 210 and microneedles 220' having a multilayer structure.
- the microneedle 220' may include a first layer 221' and a second layer 222'.
- a first base material is injected into the mold M to form the first layer 221'.
- the first layer 221' may have a curved surface.
- a second base material is injected onto the first layer 221' to form a second layer 222'.
- FIG. 13 and 14 are diagrams showing a microneedle patch manufactured by the method of manufacturing a microneedle patch according to the present invention and a comparative example.
- FIG. 13 shows 200 kDa 10% HA selected as a base material
- (a) is a microneedle patch manufactured by the manufacturing method of a microneedle patch according to an embodiment of the present invention
- (b) is a mold as a comparative example of the present invention. It is a microneedle patch manufactured by rotating to form only centrifugal force.
- the tip of the microneedle is very fine and pointed.
- the tip of the microneedle is blunt in the comparative example, it is difficult to attach the microneedle patch to the object.
- Comparative Example since the mold was not formed at a pressure lower than atmospheric pressure, the hyaluronic acid was not completely injected into the needle groove of the mold, and gas remained inside the injected hyaluronic acid, so the quality of the microneedle patch was low.
- FIG. 14 shows 1.4 MDa 10% HA selected as a base material
- (a) is a microneedle patch manufactured by the method for manufacturing a microneedle patch according to an embodiment of the present invention
- (b) is a first comparative example of the present invention.
- a microneedle patch manufactured by forming only low pressure in the mold is a microneedle patch manufactured by rotating the mold and forming only centrifugal force as a second comparative example of the present invention.
- the 1.4 MDa 10% HA of FIG. 14 has higher viscosity and higher strength than the 200 kDa 10% HA of FIG. 13 . Therefore, manufacturing a microneedle using 1.4MDa 10%HA having high viscosity is relatively more difficult than manufacturing a microneedle using 200kDa 10%HA.
- the tip of the microneedle is very fine and pointed.
- the ends of the microneedles in Comparative Example 1 and Comparative Example 2 are blunt, it is difficult to attach the microneedle patch to the object.
- the manufacturing method of the microneedle patch according to the present invention completely injects the high-molecular hyaluronic acid into the groove of the needle, thereby improving the quality of the microneedle patch.
- 1.4MDa 10%HA which is a polymer, is difficult to completely inject into the needle groove due to its high viscosity. The quality of the needle patch can be improved.
- 15 is a diagram showing an apparatus for manufacturing a microneedle patch according to another embodiment of the present invention.
- the microneedle patch manufacturing apparatus 2 may include a first injection module 10A, a second injection module 20A, and a drying module 30A.
- the apparatus 2 for manufacturing a microneedle patch shows that a first injection module 10A, a second injection module 20A, and a drying module 30A are sequentially disposed one by one, but the microneedle patch is not limited thereto. It may be variously modified according to the manufacturing process of the needle patch.
- the microneedle patch manufacturing apparatus 2 may include a plurality of at least one of the first injection module 10A, the second injection module 20A, and the drying module 30A.
- the drying module 30A may be disposed before the second injection module 20A.
- the first injection module 10A may inject the buffer solution BS into the mold M, and the second injection module 20A may place the base material BM in the mold M. . As shown in FIG. 15 , the first injection module 10A and the second injection module 20A may be provided respectively.
- the first injection module 10A may inject both the buffer solution BS and the base material BM into the mold M.
- the first injection module 10A may be integrated to inject both the buffer solution BS and the base material BM.
- the drying module 30A dries the mold M after the mold M is mounted therein.
- the buffer solution BS may be removed.
- FIG. 16 is a flowchart illustrating a method for manufacturing a microneedle patch according to another embodiment of the present invention
- FIGS. 17 to 21 are diagrams illustrating steps for manufacturing a microneedle by the method for manufacturing a microneedle patch of FIG. 16
- the method of manufacturing a microneedle patch includes filling a mold having a plurality of needle grooves with a buffer solution (S100), disposing a base material on the needle grooves (S200), and the base material. diffusing into the buffer solution (S300), and drying the mold (S400).
- the buffer solution (BS) is defined as a solution capable of dissolving the base material (BM).
- the buffer solution (BS) is a material capable of dissolving the base material (BM) forming the microneedle.
- the buffer solution BS has solubility in the base material BM and depends on the type of the base material BM.
- the buffer solution (BS) may be set as a solution capable of dissolving the base material of A.
- the buffer solution (BS) may be set to b solution capable of dissolving the base material of B.
- the buffer solution BS may be set to water, particularly purified water.
- the buffer solution (BS) may not dissolve the active ingredient (EM).
- the active ingredient (EM) is disposed inside the base material (BM), and the base material (BM) is dissolved in the buffer solution (BS), but the active ingredient (EM) is not dissolved in the buffer solution (BS).
- the active ingredient EM may be injected into the needle groove NG together with the base material BM and disposed inside the microneedle.
- the buffer solution (BS) may dissolve the active ingredient (EM).
- the active ingredient (EM) is disposed inside the base material (BM), and both the base material (BM) and the active ingredient (EM) are dissolved in the buffer solution (BS).
- the buffer solution (BS) is water and the active ingredient (EM) is water-soluble, the active ingredient (EM) may be dissolved in the buffer solution (BS).
- step S100 of filling a mold having a plurality of needle grooves with a buffer solution the mold M is filled with the buffer solution BS, and the needle groove NG is filled with the buffer solution BS (see FIG. 17 ).
- the buffer solution BS may be filled in the mold M.
- the mold M may have a base groove BG and a needle groove NG.
- the base 110 may be formed in the base groove BG, and the microneedle 320 may be formed in the needle groove NG.
- the buffer solution BS may fill the entire needle groove NG.
- the buffer solution BS may be filled only in the plurality of needle grooves NG.
- the buffer solution BS is injected only into the needle groove NG.
- the buffer solution BS may fill both the needle groove NG and the base groove BG.
- the buffer solution BS is filled in both the needle groove NG and the base groove BG, and the base material BM It can fill the entire mold (M).
- the buffer solution BS may fill only a portion of the needle groove NG.
- the buffer solution BS is injected into only a portion of the needle groove NG, and then the buffer solution BS is filled again to sequentially form the microneedle 320. can be manufactured This will be described in detail below.
- the base material BM is disposed in the mold M (see FIG. 18).
- the base material BM By disposing the base material BM on the needle groove NG, the base material BM is set to be easily dissolved in the buffer solution BS stored in the needle groove NG.
- the base material BM may be injected into the base groove BG by the nozzle 21A of the second injection module 20A.
- the base material BM Since the base material BM has a predetermined viscosity, it is difficult to directly inject it into the needle groove NG. However, since fluidity is increased when the base material BM is dissolved in the buffer solution BS, the base material BM may fill the needle groove NG.
- the base material BM is injected into the base groove BG of the mold M.
- the base material BM may completely fill the base groove BG or may be convex beyond the capacity of the base groove BG so that the base material BM sufficiently fills the needle groove NG.
- the base material BM may be dissolved in the buffer solution BS.
- the base material BM is dissolved in the buffer solution BS and injected into each needle groove NG.
- the base material BM is initially diffused from the top of the needle groove NG, and the base material BM is gradually diffused to the tip of the needle groove NG.
- the base material BM is filled in the mold M as a whole.
- the concentration of the base material BM decreases and the viscosity decreases.
- the base material BM completely fills the needle groove NG while being dissolved in the buffer solution BS. Since the base material BM completely fills the needle groove NG, the microneedle 120 may be manufactured in the shape of the needle groove NG.
- the base material BM is hyaluronic acid
- water particularly purified water
- BS buffer solution
- hyaluronic acid dissolves in water
- hyaluronic acid fills the needle groove NG.
- hyaluronic acid is a viscous material, there is a limit to filling the needle groove NG with hyaluronic acid alone.
- hyaluronic acid dissolved in water has low viscosity and high fluidity, it can fill the needle groove NG.
- the active ingredient EM may be disposed inside the base material BM.
- the base material (BM) and the active ingredient (EM) exist in a mixed form, and while the base material (BM) is dissolved in the buffer solution (BS), the active ingredient (EM) can be injected into the needle groove (NG) together. have.
- the active ingredient (EM) is not dissolved in the buffer solution (BS). Therefore, the active ingredient EM mixed in the base material BM when injected into the mold M and the active ingredient EM inside the microneedle 320 finally manufactured are the same. Since the active ingredient (EM) does not react with the buffer solution (BS), the effectiveness of the active ingredient (EM) does not change during the manufacturing process.
- the buffer solution (BS) may dissolve the active ingredient (EM).
- the active ingredient (EM) is disposed inside the base material (BM), and both the base material (BM) and the active ingredient (EM) are dissolved in the buffer solution (BS).
- the buffer solution (BS) is water and the active ingredient (EM) is water-soluble, the active ingredient (EM) may be dissolved in the buffer solution (BS). Even if the active ingredient (EM) is dissolved in the buffer solution (BS), the effect of the active ingredient (EM) does not change.
- diffusion of the base material BM may be controlled by adjusting the environment.
- the diffusion speed of the base material BM may be increased by adjusting the temperature or humidity inside the chamber where the mold M is located.
- the diffusion rate of the base material BM may be increased by injecting an additive (not shown) increasing the diffusion rate into the buffer solution BS.
- the mold M may be mounted on a stirrer (not shown), and the diffusion rate of the base material BM may be increased by vibration generated by driving the stirrer.
- the microneedle 320 may be manufactured by drying the buffer solution (BS) (see FIG. 21).
- the mold M is mounted on the drying module 30A, and the drying module 30A is driven to dry the mold M.
- the buffer solution BS stored in the base mold M may be removed by the drying module 30A.
- the concentration of the base material BM increases. Then, since the buffer solution BS is completely removed and the moisture included in the base material BM is also removed, the microneedle 320 made of the base material BM is created.
- the base material BM is changed into a solid, and the microneedles 320 have a predetermined rigidity.
- the microneedle 320 molded in solid has an active ingredient (EM) therein.
- the active ingredient (EM) remains included in the base material (BM).
- a base material (BM) suitable for forming microneedles has a predetermined viscosity. Since the needle groove NG of the mold M is manufactured very finely, it is difficult to completely fill the needle groove NG with the viscous base material BM.
- the tip of the microneedle is formed bluntly. Since the microneedle 320 is to be inserted through the skin of a subject, the end of the microneedle 320 must be manufactured in the shape of a sharpened tip. However, the viscous base material BM does not completely fill the needle groove NG, and the microneedle 320 is formed bluntly by the empty space, making it difficult for the microneedle 320 to attach to the object, decrease the drug delivery effect.
- gas such as air may be stored in the viscous base material BM in the form of bubbles during the manufacturing process of the microneedle patch 300 . Even if the base material BM is squeezed and injected into the needle groove NG, internal bubbles may still exist in the needle groove NG. The gas remaining in the internal bubble of the base material BM may seriously degrade the quality of the microneedle 320 . Since the microneedle 320 is a part to be implanted into the skin of a subject, it should not contain foreign substances including gas. If the gas in the bubble is injected into the object, it may threaten the safety of the object.
- a microneedle patch having an elaborate shape and improved quality can be manufactured by completely filling a mold with a base material. Since the base material is completely filled in the needle groove by the buffer solution, the microneedle has a sharpened tip shape, so it can be easily attached to the skin of a subject. In addition, since foreign matter such as air is not injected into the needle groove during the manufacturing process, a high-quality microneedle patch can be manufactured.
- 1.4MDa 10% HA which is a polymer
- the polymer 1.4MDa 10% HA has relatively high viscosity, it is difficult to completely inject into the mold.
- the manufacturing method of the microneedle patch according to the present invention when purified water as a buffer solution is injected into the mold and 1.4MDa 10% HA as a polymer is dissolved in the buffer solution, the base material is completely injected into the needle groove. Then, when the purified water is dried, microneedles having the same shape as the needle groove are manufactured.
- the method for manufacturing a microneedle patch according to the present invention can manufacture a microneedle patch having a complex and detailed needle shape.
- the base material is diffused into the buffer solution during the manufacturing process of the microneedle patch, the viscosity of the base material is lowered and the fluidity is increased. Even if the shape of the needle groove is complex and very sophisticated, the base material can completely fill the needle groove by fluidity.
- the microneedle patch 300 may include a base 310 and single-layer microneedles 320 using the above-described microneedle patch manufacturing apparatus 2 or the microneedle patch manufacturing method.
- the microneedle 320 may contain an active ingredient (EM) therein.
- the microneedle patch 300 may be applied with the base material BM and the effective part EM of the microneedle patch 100 described above.
- the microneedle 320 is formed by dissolving the base material BM in the buffer solution and then drying the buffer solution BS. At this time, the buffer solution BS may be completely removed.
- the buffer solution may include water, and the base material BM may include hyaluronic acid.
- the active ingredient (EM) is disposed inside the base material (BM), and the active ingredient (EM) may not be dissolved in the buffer solution.
- 23 to 25 are diagrams illustrating other embodiments of the microneedle patch of FIG. 22 .
- the microneedle patch 400 may be manufactured by the above-described microneedle patch manufacturing apparatus 2 or the microneedle patch manufacturing method.
- the microneedle patch 420 may have a base 410 and microneedles 420 having a multilayer structure.
- the microneedle patch 400 having a multilayer structure can be manufactured.
- the first buffer solution is injected into the needle groove NG.
- the first buffer solution does not completely fill the needle groove NG.
- the first buffer solution is filled to have a larger volume than the volume of the first layer 421 .
- the first buffer solution may be filled to a height h1' greater than h1 in FIG. 23 .
- the first base material BM1 is disposed in the mold M, and the first base material BM1 is diffused into the first buffer solution. Since the first base material BM1 is dissolved in the first buffer solution, the tip of the needle groove NG is filled with the first base material BM1.
- the mold M filled with the first buffer solution and the first base material BM1 is dried to remove the first buffer solution.
- the first layer 421 is formed of the first base material BM1 at the tip of the needle groove NG.
- the height of the first layer 421 is h1.
- the second buffer solution is injected into the needle groove NG.
- the second buffer solution is filled on top of the first layer 421 in the needle groove NG.
- the second base material BM2 is disposed in the mold M, and the second base material BM2 is diffused into the second buffer solution. Since the second base material BM2 is dissolved in the second buffer solution, the second base material BM2 is filled on the first layer 421 .
- the mold M filled with the second buffer solution and the second base material BM2 is dried to remove the second buffer solution. Accordingly, since the second layer 422 is formed of the second base material BM2 on the first layer 421, the microneedle 420 has a multilayer structure.
- At least one of the first layer 421 and the second layer 422 may have an active ingredient.
- the first active ingredient EM1 may be disposed on the first layer 421 and the second active ingredient EM2 may be disposed on the second layer 422 .
- EM1 first active ingredient
- EM2 second active ingredient
- a plurality of types of active ingredients may be mixed in each layer.
- the first layer 421 may have greater strength than the second layer 422 .
- the first layer 421 is additionally subjected to a drying process during the manufacturing process of the second layer 422 .
- Strength of the first layer 421 may be enhanced by an additional drying process. When the strength of the first layer 421 is enhanced, the microneedle patch 400 can be easily attached to the skin of a subject.
- the second buffer solution may dissolve only the second base material BM2 and not dissolve the first base material BM1.
- the first layer 421 made of the first base material BM1 may not be melted by the second buffer solution. have.
- the target positions of the first layer 421 and the second layer 422 can be clearly distinguished.
- the microneedles 420 disposed on one surface of the base 410 have a multi-layered structure, so that the active ingredient (EM) can be accurately delivered to the target point. Since the microneedle 420 has a multi-layered structure, active ingredients can be loaded into each layer. For example, the first active ingredient EM1 may be loaded on the first layer 421 and the second active ingredient EM2 may be loaded on the second layer 422 . Thus, the microneedle patch 400 can adjust the active depth of each active ingredient according to the height of the layer. That is, the microneedle patch 400 can deliver active ingredients to any one of epidermis, dermis, subcutaneous fat, and muscle.
- the microneedle patch 400 has a multi-layered structure, and the biodegradation rate of each layer can be set differently.
- the microneedle 420 sets the decomposition rate of the first layer 421 and the second layer 422 differently, so that the first active ingredient EM1 and the second active ingredient EM2 can have different active times. have.
- the microneedle patch 400 has a multi-layer structure, and the strength of each layer can be set differently. By setting the strength of the first layer 421 higher than that of the second layer 422, the microneedle 420 can be easily injected into the skin.
- the microneedle patch 400A may have a base 410 and microneedles 420A.
- a first layer 421A, a second layer 422A, and a transition layer 423A between the first layer 421 and the second layer 422 may be formed.
- the transition layer 423A may have a mixed form of the first base material BM1 and the second base material BM2.
- the second buffer solution may dissolve both the second base material BM2 and the first base material BM1.
- the second buffer solution is injected into the needle groove NG after the first layer 421A made of the first base material BM1 is formed, a portion of the upper surface of the first layer 421A may be dissolved.
- a transition layer 423A may be formed in a boundary region between the first layer 421A and the second layer 422A.
- the first base material BM1 dissolved in the first layer 421A and the additionally injected second base material BM2 may have a mixed form.
- the transition layer 423A may increase the bonding force between the first layer 421A and the second layer 422A, thereby increasing the strength of the microneedle 420A. Due to the transition layer 423A, the characteristics of the first layer 421A and the second layer 422A do not change rapidly, and the bonding force between the first layer 421A and the second layer 422A can be increased.
- the microneedle patch 400B may be manufactured by the above-described microneedle patch manufacturing apparatus 2 or the microneedle patch manufacturing method.
- the microneedle patch 420B may have a base 410B and microneedles 420B having a multilayer structure.
- the microneedle 420B may include a first layer 421B and a second layer 422B having a layered structure.
- the first base material BM1 is injected into the mold M filled with the first buffer solution.
- the first layer 421B made of the first base material BM1 may have a curved surface.
- the mold M is filled with the second buffer solution, and the second base material BM2 is diffused into the second buffer solution.
- a second layer 422B may be formed on the first layer 421B.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Mechanical Engineering (AREA)
- Hematology (AREA)
- Medical Informatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Anesthesiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Abstract
Description
Claims (13)
- 복수개의 니들 홈을 가지는 몰드에 베이스 물질을 채우는 단계;상기 몰드에 대기압 보다 낮은 압력을 형성하는 단계;상기 몰드를 회전축에 대하여 회전시키는 단계; 및상기 니들 홈에 채워진 상기 베이스 물질을 건조하는 단계;를 포함하는, 마이크로니들 패치의 제조 방법.
- 제1 항에 있어서,상기 몰드에 대기압 보다 낮은 압력을 형성하는 단계는상기 니들 홈에 채워진 상기 베이스 물질의 내부 버블을 제거하거나, 상기 베이스 물질과 상기 니들 홈 사이의 기체가 제거되는, 마이크로니들 패치의 제조 방법.
- 제1 항에 있어서,상기 몰드를 회전축에 대하여 회전시키는 단계는원심력에 의해서 상기 베이스 물질을 상기 니들 홈의 축 방향으로 밀착시키는, 마이크로니들 패치의 제조 방법.
- 제1 항에 있어서,상기 몰드에 대기압 보다 낮은 압력을 형성하는 단계 이전에, 상기 베이스 물질이 채워진 상기 몰드를 상기 회전축에 대하여 미리 회전시키는 단계;를 더 포함하는, 마이크로니들 패치의 제조 방법.
- 제1 항에 있어서,상기 회전축은 상기 니들 홈의 축 방향과 수직되는, 마이크로니들 패치의 제조 방법.
- 베이스 물질이 주입되는 복수개의 니들 홈을 가지는 몰드;상기 몰드에 대기압 보다 낮은 압력을 형성하는 압력 모듈;회전축을 중심으로 상기 몰드를 회전시키는 회전 모듈; 및상기 니들 홈에 채워진 상기 베이스 물질을 건조시키는 건조 모듈;을 포함하는, 마이크로니들 패치의 제조 장치.
- 제6 항에 있어서,상기 베이스 물질은상기 압력 모듈에서 상기 베이스 물질의 내부 버블이 제거되거나, 상기 베이스 물질과 상기 니들 홈 사이의 기체가 제거된 이후에,상기 회전 모듈의 구동으로 생성된 원심력으로, 상기 베이스 물질이 니들 홈의 축 방향으로 밀착되는, 마이크로니들 패치의 제조 장치.
- 복수개의 니들 홈을 가지는 몰드에 버퍼 용액을 채우는 단계;상기 니들 홈의 위에 베이스 물질을 배치하는 단계;상기 베이스 물질을 상기 버퍼 용액으로 확산시키는 단계; 및상기 몰드를 건조하는 단계;를 포함하는, 마이크로니들 패치의 제조 방법.
- 제8 항에 있어서,상기 베이스 물질을 상기 버퍼 용액으로 확산시키는 단계는상기 베이스 물질이 상기 니들 홈으로 주입되는, 마이크로니들 패치의 제조 방법.
- 제9 항에 있어서,상기 버퍼 용액은 상기 베이스 물질을 용해시키는, 마이크로니들 패치의 제조 방법.
- 제10 항에 있어서,상기 버퍼 용액은 물을 포함하고, 상기 베이스 물질은 히알루론산(hyaluronic acid)를 포함하는, 마이크로니들 패치의 제조 방법.
- 제10 항에 있어서,상기 베이스 물질의 내부에는 유효 성분이 배치되는, 마이크로니들 패치의 제조 방법.
- 제8 항에 있어서,상기 몰드를 건조하는 단계는상기 버퍼 용액이 제거되어, 상기 베이스 물질이 상기 니들 홈에서 굳는, 마이크로니들 패치의 제조 방법.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/628,728 US20230364401A1 (en) | 2021-05-12 | 2021-10-25 | Microneedle patch, method of manufacturing microneedle patch, and apparatus for manufacturing microneedle patch |
EP21840769.0A EP4338783A1 (en) | 2021-05-12 | 2021-10-25 | Microneedle patch, method of manufacturing microneedle patch, and apparatus for manufacturing microneedle patch |
JP2022505232A JP2023529034A (ja) | 2021-05-12 | 2021-10-25 | マイクロニードルパッチ、マイクロニードルパッチの製造方法及びマイクロニールパッチの製造装置 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2021-0061451 | 2021-05-12 | ||
KR10-2021-0061417 | 2021-05-12 | ||
KR1020210061417A KR20220153881A (ko) | 2021-05-12 | 2021-05-12 | 마이크로니들 패치의 제조 방법 및 마이크로니들 패치의 제조 장치 |
KR1020210061451A KR102611702B1 (ko) | 2021-05-12 | 2021-05-12 | 마이크로니들 패치의 제조 방법 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022239915A1 true WO2022239915A1 (ko) | 2022-11-17 |
Family
ID=84029228
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/015027 WO2022239915A1 (ko) | 2021-05-12 | 2021-10-25 | 마이크로니들 패치, 마이크로니들 패치의 제조 방법 및 마이크로니들 패치의 제조 장치 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20230364401A1 (ko) |
EP (1) | EP4338783A1 (ko) |
JP (1) | JP2023529034A (ko) |
WO (1) | WO2022239915A1 (ko) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009273772A (ja) * | 2008-05-16 | 2009-11-26 | Kyokko Seiko Co Ltd | マイクロニードルシート並びにその製造方法及び製造装置 |
KR20110012986A (ko) * | 2009-07-31 | 2011-02-09 | 임병진 | 마이크로니들 패드 제조방법 및 이를 위한 제조장치 |
KR20170118668A (ko) * | 2015-02-13 | 2017-10-25 | 주식회사 엔도더마 | 가교된 히알루론산 하이드로젤을 이용한 마이크로구조체 및 이의 제조방법 |
KR101905040B1 (ko) * | 2017-04-19 | 2018-10-08 | (주) 오스타테크 | 마이크로 니들 충전장치 및 충전방법 |
WO2019221318A1 (ko) * | 2018-05-18 | 2019-11-21 | 포항공과대학교 산학협력단 | 경피 투과형 약물 전달 패치 및 이의 제조 방법 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106232159B (zh) * | 2014-04-24 | 2021-10-08 | 佐治亚科技研究公司 | 微针和其制造方法 |
JP6682783B2 (ja) * | 2015-09-08 | 2020-04-15 | 凸版印刷株式会社 | 経皮投与デバイス、および、経皮投与デバイスの製造方法 |
EP3416621B1 (en) * | 2016-02-19 | 2023-12-20 | North Carolina State University | Physiologically responsive microneedle delivery systems |
WO2018098343A1 (en) * | 2016-11-23 | 2018-05-31 | University Medical Pharmaceuticals Corp. | Microneedle delivery system and method |
EP3694487A1 (en) * | 2017-10-11 | 2020-08-19 | Georgia Tech Research Corporation | Separable microneedle arrays for sustained release of drug |
JP2022553337A (ja) * | 2019-10-22 | 2022-12-22 | ジョージア テック リサーチ コーポレイション | 流延配合物中の成分溶解度の調整を使用してマイクロニードルを作製するための方法 |
-
2021
- 2021-10-25 EP EP21840769.0A patent/EP4338783A1/en active Pending
- 2021-10-25 WO PCT/KR2021/015027 patent/WO2022239915A1/ko active Application Filing
- 2021-10-25 JP JP2022505232A patent/JP2023529034A/ja active Pending
- 2021-10-25 US US17/628,728 patent/US20230364401A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009273772A (ja) * | 2008-05-16 | 2009-11-26 | Kyokko Seiko Co Ltd | マイクロニードルシート並びにその製造方法及び製造装置 |
KR20110012986A (ko) * | 2009-07-31 | 2011-02-09 | 임병진 | 마이크로니들 패드 제조방법 및 이를 위한 제조장치 |
KR20170118668A (ko) * | 2015-02-13 | 2017-10-25 | 주식회사 엔도더마 | 가교된 히알루론산 하이드로젤을 이용한 마이크로구조체 및 이의 제조방법 |
KR101905040B1 (ko) * | 2017-04-19 | 2018-10-08 | (주) 오스타테크 | 마이크로 니들 충전장치 및 충전방법 |
WO2019221318A1 (ko) * | 2018-05-18 | 2019-11-21 | 포항공과대학교 산학협력단 | 경피 투과형 약물 전달 패치 및 이의 제조 방법 |
Also Published As
Publication number | Publication date |
---|---|
US20230364401A1 (en) | 2023-11-16 |
EP4338783A1 (en) | 2024-03-20 |
JP2023529034A (ja) | 2023-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2019198936A1 (ko) | 마이크로 니들 및 마이크로 니들의 제조방법 | |
WO2018093218A1 (ko) | 복합 제형이 적용된 마이크로니들 어레이 및 이의 제조방법 | |
WO2017150824A1 (ko) | 마이크로 니들 및 이의 제조방법 | |
WO2016099159A1 (ko) | 미세방 마이크로구조체 및 이의 제조방법 | |
WO2017176045A2 (ko) | 효율적인 피부 천공을 위한 마이크로니들 구조 | |
WO2022239915A1 (ko) | 마이크로니들 패치, 마이크로니들 패치의 제조 방법 및 마이크로니들 패치의 제조 장치 | |
WO2023120850A1 (ko) | 마이크로니들 패치의 제조 장치 및 마이크로니들 패치의 제조 방법 | |
WO2022234905A1 (ko) | 마이크로니들 패치 | |
WO2018079990A1 (ko) | 마이크로 니들 패치, 마이크로 니들을 제조하는 방법 및 장치 | |
WO2020153802A1 (ko) | 3층 이상 구조의 마이크로 니들 및 이의 제조방법 | |
WO2020060195A1 (ko) | 미세 구조체 기반 약물 주입장치 및 이의 제조 방법 | |
WO2019146884A1 (ko) | 마이크로 니들 및 이의 제조방법 | |
WO2023017906A1 (ko) | 마이크로니들 패치 | |
WO2023120808A1 (ko) | 마이크로니들 패치 제조 방법 | |
WO2020184909A1 (ko) | 3층 이상 구조의 마이크로 니들 및 이의 제조방법 | |
WO2023120897A1 (ko) | 마이크로니들 제조 장치 및 마이크로니들 제조 방법 | |
WO2024005439A1 (ko) | 마이크로니들 패치 제조 시스템 및 마이크로니들 패치 제조 방법 | |
WO2023120810A1 (ko) | 마이크로니들 제조 장치 및 마이크로니들 제조 방법 | |
WO2022005177A1 (ko) | 전기수력학 프린팅을 이용한 마이크로니들 패치 제조 장치 및 제조 방법 | |
WO2017010813A1 (ko) | 고형물의 유동화를 이용한 마이크로구조체 및 이의 제조방법 | |
KR102611702B1 (ko) | 마이크로니들 패치의 제조 방법 | |
WO2023286916A1 (ko) | 마이크로니들 패치 및 마이크로니들 패치 제조방법 | |
WO2023017907A1 (ko) | 마이크로니들 패치 | |
KR20220153881A (ko) | 마이크로니들 패치의 제조 방법 및 마이크로니들 패치의 제조 장치 | |
WO2023146061A1 (ko) | 마이크로니들 패치의 제조 방법 및 마이크로니들 패치의 제조 장치 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2022505232 Country of ref document: JP Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21840769 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2021840769 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021840769 Country of ref document: EP Effective date: 20231212 |